-
Pharosight: A Shiny-Based Interactive Platform With LLM-Enhanced Analyses and Predictive Modeling for Real-World Prescription Data
Sep 9, 2025, 16:22 PM -
Real-World Treatment Patterns Among Patients Newly Diagnosed With Chronic Inflammatory Demyelinating Polyneuropathy in the United States
Sep 9, 2025, 16:22 PM -
Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma
Sep 9, 2025, 16:22 PM -
Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Epidemiological Characteristics and Economic Burden of IgA Nephropathy—a Retrospective Study Using Multicenter Electronic Medical Records Data in China
Sep 9, 2025, 16:22 PM -
Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework
Sep 9, 2025, 16:22 PM -
Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study
Sep 9, 2025, 16:22 PM -
The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
Sep 9, 2025, 16:22 PM -
Saving Money Improving Outcomes: A Two-Year Cost-Utility Analysis of Emergency Department Care Models for Managing Persons Presenting With a Musculoskeletal Disorder
Sep 9, 2025, 16:22 PM -
What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques
Sep 9, 2025, 16:22 PM -
Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach
Sep 9, 2025, 16:22 PM -
Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease
Sep 9, 2025, 16:22 PM -
CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Sep 9, 2025, 16:22 PM -
Development and Assessment of a Portability Strategy for Computable Operational Definitions
Sep 9, 2025, 16:22 PM -
Methodological Insights From Recent PBAC Recommendations to Support Biosimilar Reimbursement in Australia
Sep 9, 2025, 16:22 PM -
Occurrence of Exacerbations and Mortality in High-Risk Chronic Obstructive Pulmonary Disease Patients While on Treatment With Dual or Triple Inhaled Therapy: Results From the SIRIUS Observational Study in the US
Sep 9, 2025, 16:22 PM -
HTA and Regulatory Perspectives on Robustness of Evidence and Management of Uncertainties
Sep 9, 2025, 16:22 PM -
Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?
Sep 9, 2025, 16:22 PM -
Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico
Sep 9, 2025, 16:22 PM
